HUTCHMED Communications on Groundbreaking R&D Updates
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13), a prominent biopharmaceutical company, is gearing up to present a comprehensive update on its research and development initiatives. This exciting event will take place in Shanghai and will also be accessible through a live webcast for global audiences. While the in-person gathering is by invitation only, those interested in HUTCHMED's innovation will have the opportunity to tune into the webcast on October 31.
Understanding HUTCHMED's Developmental Goals
Dr. Michael Shi, Executive Vice President and Chief Medical Officer at HUTCHMED, will guide participants through the company’s ambitious R&D strategy. He will highlight the progress made with their Antibody Targeted Therapy Conjugates platform, particularly focusing on HMPL-A251, which is a lead candidate showcasing the company's commitment to pioneering advancements in cancer treatment. Updates on other projects in the late-stage pipeline will also be shared, underscoring HUTCHMED’s progressive vision for the future.
Event Format and Learning Opportunities
This pivotal event is scheduled to take place in Shanghai from 3:00 p.m. to 5:00 p.m. HKT and will be conducted in Putonghua, allowing an inclusive experience for participants fluent in Chinese. A convenient live webcast in English will follow at 8:00 p.m. HKT, providing insight to a broader audience. The live discussions promise to be rich with information, lasting about one hour and enabling viewers to access valuable knowledge regarding the company's innovative strides.
Accessing the Live Webcast
If you're unable to attend in person, you can easily join the live webcast via HUTCHMED's company website. Additionally, a replay will be available shortly after the event, ensuring that everyone interested can catch up on key discussions and announcements made during the presentations.
About HUTCHMED: A Leader in Biopharmaceuticals
HUTCHMED is an innovative and commercial-stage biopharmaceutical company dedicated to the discovery and global development of targeted therapies, particularly in oncology and immunology. HUTCHMED strives to bring its innovative drug candidates from research labs to the hands of patients worldwide. The pride of the company lies within its track record, having successfully launched three key medicines in China, with further approvals extending to international markets including the US, Europe, and Japan.
Staying Connected with HUTCHMED
For those wanting to learn more about HUTCHMED, their website is an excellent resource, filled with information regarding their products, research initiatives, and corporate missions. Furthermore, by following their social media platforms, audiences can stay updated on their meaningful advancements in biopharmaceutical innovations.
Frequently Asked Questions
What is the date and time of HUTCHMED's R&D update?
The R&D update event will occur on October 31 from 3:00 p.m. to 5:00 p.m. HKT in Shanghai.
Who will be presenting at the R&D update?
Dr. Michael Shi, Executive Vice President and Chief Medical Officer of HUTCHMED, will be the keynote presenter.
How can I attend the R&D update?
The event will be held in person by invitation only, but a live webcast will be available for a broader audience.
What is HMPL-A251?
HMPL-A251 is a lead candidate under HUTCHMED's Antibody Targeted Therapy Conjugates platform, aimed at developing novel cancer treatments.
Where can I access the replay of the event?
The replay of the event will be available on HUTCHMED's company website following the live presentations.
